Gloria  Espinosa, PharmD, MAT, BCOP, on Safety of Quizartinib by Treatment Phase and Age in FLT3-ITD–Positive Acute Myeloid Leukemia

Gloria  Espinosa, PharmD, MAT, BCOP, of Thomas Jefferson University Hospital, comments on the safety data of the FLT3 inhibitor quizartinib in patients with FLT3-ITD–positive acute myeloid leukemia. Infections and cytopenias were observed with quizartinib, and patients older than 65 had higher rates of serious treatment-emergent adverse events (Abstract 972).